drugset / Trial / NCT00747110

Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)

NCT00747110

Phase 3 Completed 343 enrolled Dr. Falk Pharma GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to prove the therapeutic equivalence and safety of once-daily 9 mg budesonide versus 3 g mesalazine in a 8-week treatment in patients with active ulcerative colitis.

Timeline

Start
2007-10
Primary completion
2008-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 9 mg Oral
Comparator Mesalamine Small molecule 3 g Oral

Indications